Data / Drug companies / Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC: 484 products in the FDA NDC directory, labeler code 63323
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Fresenius Kabi USA, LLC (labeler code 63323) lists 484 products in the FDA National Drug Code Directory, covering 163 finished drugs by generic name. By type: 484 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 25, 2025.
The request: Watch Fresenius Kabi USA, LLC (FDA labeler code 63323): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 63323
- Products in commercial distribution
- 484
- Packages
- 656
- Finished drugs by generic name
- 163
- Prescription products
- 484
- Over the counter products
- 0
- Controlled substance products
- Schedule II 16, Schedule IV 2
- Flagged as original packager
- 471 of 471 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- February 22, 1972
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 338 | 69.8% |
| New drug applications (NDA) | 127 | 26.2% |
| Authorized generics (NDA) | 16 | 3.3% |
| Other unapproved drugs | 2 | 0.4% |
| Biologics (BLA) | 1 | 0.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 484 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 258 | 53.3% |
| Injection, powder, lyophilized, for solution | 99 | 20.5% |
| Injection | 52 | 10.7% |
| Injection, powder, for solution | 34 | 7% |
| Solution | 10 | 2.1% |
| Injection, solution, concentrate | 9 | 1.9% |
| Injection, emulsion | 8 | 1.7% |
| Powder, for solution | 7 | 1.4% |
| Kit | 6 | 1.2% |
| Inhalant | 1 | 0.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sodium Bicarbonate | 63323-089 | Injection, solution | Generic drugs (ANDA) | August 25, 2025 |
| Sodium Bicarbonate | 63323-083 | Injection, solution | Generic drugs (ANDA) | August 25, 2025 |
| Epinephrine | 63323-698 | Injection, solution, concentrate | New drug applications (NDA) | March 13, 2025 |
| Calcitonin Salmon | 63323-865 | Injection, solution | Generic drugs (ANDA) | December 5, 2024 |
| Epinephrine | 63323-696 | Injection, solution, concentrate | Generic drugs (ANDA) | November 21, 2024 |
| Posaconazole | 63323-685 | Injection, solution | Generic drugs (ANDA) | December 26, 2023 |
| Sodium Chloride | 63323-099 | Injection, solution, concentrate | Generic drugs (ANDA) | July 11, 2023 |
| Vasopressin | 63323-930 | Injection, solution | Generic drugs (ANDA) | May 26, 2023 |
| Sincalide | 63323-579 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | April 1, 2023 |
| Pemetrexed | 63323-622 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Pemetrexed | 63323-621 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Pemetrexed | 63323-450 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Pemetrexed | 63323-134 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Bortezomib | 63323-821 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Sodium Phosphates | 63323-886 | Injection, solution | Generic drugs (ANDA) | March 30, 2022 |
| Sodium Phosphates | 63323-884 | Injection, solution | Generic drugs (ANDA) | March 30, 2022 |
| Sodium Phosphates | 63323-881 | Injection, solution | Generic drugs (ANDA) | March 30, 2022 |
| Sodium Chloride | 63323-095 | Injection, solution, concentrate | Generic drugs (ANDA) | February 14, 2022 |
| Romidepsin | 63323-926 | Kit | Generic drugs (ANDA) | October 12, 2021 |
| Potassium Chloride in Sodium Chloride | 63323-688 | Injection, solution | Generic drugs (ANDA) | June 2, 2021 |
| Potassium Chloride in Sodium Chloride | 63323-686 | Injection, solution | Generic drugs (ANDA) | June 2, 2021 |
| Potassium Chloride in Sodium Chloride | 63323-683 | Injection, solution | Generic drugs (ANDA) | June 2, 2021 |
| Vancomycin hydrochloride | 63323-284 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 3, 2021 |
| Vancomycin hydrochloride | 63323-221 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 3, 2021 |
| Sodium Chloride | 63323-093 | Injection, solution, concentrate | Generic drugs (ANDA) | April 28, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.